The other question is whether patients with adenoid cystic carcinoma will profit from combined treatment with i.e. new substances such as EGFR-inhibitors, which will potentially not increase treatment-related side effects significantly [23,28] in terms of local and distant control. This evidence concerns the gene EGFR and adenoid cystic carcinoma.